Methotrexate Pfizer (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into its active form. This interruption reduces the production of nucleotides needed for DNA synthesis, thereby limiting the growth of rapidly dividing cells such as cancer cells and immune cells involved in inflammation.

The specific dose and schedule of Methotrexate Pfizer are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment goals. Dosing may be weekly or as part of a chemotherapy regimen, and it should always follow the prescriber’s instructions.

Methotrexate is contraindicated in pregnancy because it can cause fetal malformations and miscarriage. Women of child‑bearing potential must use effective contraception. It is also not recommended while breastfeeding, as it can be excreted in breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Methotrexate shares a similar mechanism with other antimetabolites like pemetrexed, but it is distinguished by its broad range of approved indications, including both inflammatory diseases and several cancers. Its dosing flexibility and extensive clinical experience make it a cornerstone therapy, though safety monitoring is critical.

Methotrexate Pfizer should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid freezing. Follow any additional handling instructions provided by the supplier.

Methotrexate Pfizer can be given by intra‑arterial, intramuscular, or intravenous injection, depending on the indication and clinical protocol. Administration is performed by qualified healthcare professionals in a controlled setting, with appropriate monitoring for adverse reactions.

The most serious risks include severe liver toxicity, pulmonary fibrosis, bone‑marrow suppression leading to pancytopenia, and acute renal failure. Patients should be monitored regularly for liver enzymes, blood counts, and renal function, and any signs of infection or respiratory distress require immediate medical attention.

Methotrexate is contraindicated in patients with known hypersensitivity to the drug, severe renal or hepatic impairment, active infections, and in pregnant or breastfeeding women. Caution is also advised for individuals with pre‑existing blood disorders or pulmonary disease.